VANCOUVER, British Columbia, Jan. 09, 2018 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (RHT.V) or (RQHTF) (“Reliq” or the “Company”), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce further to its news release dated December 12, 2017, it successfully closed an oversubscribed private placement (the “Offering”) led by Canaccord Genuity Corp and Gravitas Securities Inc. (together, the “ Agents”) of 8,928,571 Units (the “Units”) of the Company at a price of $1.12 per Unit (the “Unit Price”) for gross proceeds of approximately $10,000,000.

Each Unit consists of one (1) common share of the Company (a “Common Share”) and half of one (1/2) Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each of the 4,464,285 Warrants is exercisable to acquire one Common Share (a “Warrant Share”) for a period of two years following the closing date of the Offering at an exercise price of $1.75 per Warrant Share, subject to adjustment in certain events.

The Company intends to use the net proceeds of the Offering for general working capital, product development and customer acquisition.

In connection with the Offering, the Company paid the Agents a cash fee of approximately $800,000 and issued 446,428 Units to the Agents. Additionally, the Company issued 714,285 compensation warrants to the Agents and another selling dealer group member (the “Compensation Warrants”), with each Compensation Warrant entitling the holder to purchase one Unit of the Company at an exercise price of $1.12 for a period of two years following the closing date of the Offering. Each warrant issued under the Units is exercisable into one Common Share of the Company for a period of two years following the closing date of the Offering at an exercise price of $1.75 per Common Share, subject to adjustment in certain events.

All securities issued in connection with the Offering are subject to a four month hold period expiring May 10, 2018.

“Dr. Lisa Crossley”
CEO and Director

For further information contact:
CORE Capital Partners at 604-566-9233 or

Renmark Financial Communications Inc.
Laura Welsh:
Tel: (416) 644-2020 or (514) 939-3989

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws.  All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.